Amgen To Pay $25M To Escape Anemia Drug Kickback Suit

Law360, New York (April 16, 2013, 6:50 PM EDT) -- Amgen Inc., which pled guilty in December to misbranding its Aranesp anemia drug, will pay $24.9 million to settle a whistleblower suit alleging it paid kickbacks to pharmacy providers to promote the drug among Medicare and Medicaid patients, the U.S. Department of Justice said Tuesday.

The DOJ announced the settlement after intervening in the False Claims Act complaint, which was filed under seal in South Carolina federal court by former Amgen employee Frank Kurnik.

The deal resolves allegations that Amgen paid kickbacks to Omnicare Inc., PharMerica...
To view the full article, register now.